Remote, no facility visits. Managed by PepsiCo R&D Life Sciences
Chicago, Illinois, 60661, United States
NCT Number: NCT06191822
This non-randomized pilot study program is focused on assessing the technical characteristics of the Aspire2B mobile device application.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Chicago, Illinois, 60661, United States
Aspire2B is a mobile wellness app that uses non-invasive measurements to predict various physiological states and estimate biological age. Users are then enrolled in nutrition, fitness, or sleep challenges within the app that are aimed at improving overall wellness and thus helping to reduce biological age. Mobile health (mHealth) interventions require numerous decisions that integrate behavioral theory, user feedback, and technical and practical feasibility considerations. The main purpose of this research program is to test if the application works as intended. This pilot study program is managed internally by Pepsico clinical researchers.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Interact with mobile app and work toward personalized nutrition goals
Interact with mobile app and work toward personalized fitness goals
Interact with mobile app and work toward personalized sleep goals
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Ability to connect wearable devices
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Ability to conduct face scan to provide biological age
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Ability to conduct face scan to provide stress index
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Ability to conduct face scan to provide heart rate
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Onboarding sequence
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Ability to enter own goal
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Ability to track and measure goal progress (e.g., steps from a wearable device)
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Do points earned reflect what was completed in the app?
Time frame: Continuous for up to 6 weeks
Does the app work as intended: Does wellness score change with lifestyle changes as intended? An improved wellness score is better.
Time frame: Continuous for up to 6 weeks
Exploratory analyses of the data aimed to help to inform clinical trial retention rates
Time frame: Continuous for up to 6 weeks
Exploratory analyses of the data aimed to help to inform predictors of engagement
Time frame: Continuous for up to 6 weeks
Exploratory analyses of the data aimed at informing engagement with specific app features
Time frame: Continuous for up to 6 weeks
Exploratory analyses of the data aimed at informing improvements in self-reported diet behaviors
Time frame: Continuous for up to 6 weeks
Exploratory analyses of the data aimed at informing improvements in self-reported lifestyle behaviors
PepsiCo Global R&D
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03565731
ACT, Acceptance and Commitment Therapy
Providence, Rhode Island, United States
View Trial DetailsNCT02496312
Apathy, Behavior
Paris, France
View Trial DetailsNCT04826276
Behavior
Winston-Salem, North Carolina, United States
View Trial DetailsNCT05715190
Behavior, Health Behavior
Lausanne, Canton of Vaud, Switzerland
View Trial Details